Research Article
Is Drug Resistance in First-Line Therapy against All Antiretroviral Agents Inevitable?
| Mark A Wainberg* and Thibault Mesplède | ||
| McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Chemin-Côte-Ste-Catherine, Montréal, H3T 1E2, Québec,Canada | ||
| Corresponding Author : | Mark A Wainberg McGill University AIDS Centre Lady Davis Institute for Medical Research Jewish General Hospital, 3755 Chemin-Côte-Ste- Catherine, Montreal, Quebec H3T 1E2, Canada Tel: 514-340-8260 Fax: 514-340-7537 E-mail: mark.wainberg@mcgill.ca |
|
| Received December 06, 2014; Accepted March 20, 2015; Published March 27, 2015 | ||
| Citation: Wainberg MA, Mesplède T (2015) Is Drug Resistance in First-Line Therapy against All Antiretroviral Agents Inevitable?. J Infect Dis Ther 3:208. doi: 10.4172/2332-0877-1000208 | ||
| Copyright: © 2015 Wainberg MA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | ||
Related article at |
||
Abstract
Drug resistance has been observed in regard to all anti-retroviral drugs that have been studied until now. The most recent drug to be approved for use in HIV therapy is dolutegravir, an HIV integrase inhibitor, that was approved for therapy by the Food and Drug Administration in the United States in 2013. Dolutegravir is the only HIV drug that has not selected for resistance mutations in the clinic when used as part of first-line therapy. We have hypothesized that this is due to the long binding time of dolutegravir to the integrase enzyme as well as greatly diminished replication capacity on the part of viruses that might become resistant to dolutegravir and that are unable to successfully replicate in infected individuals.
